I want to share both of these posts which appeared today on another site for Gastroparesis and DTP sufferers. They were shared by a woman named Colleen who works tirelessly to help all of us get the attention and action needed to find the solution to our issues. It's people like her who really deserve our gratitude. Without them we would have no hope!
Thank you Colleen.
"The FDA has had success when they have held meetings with patients from organizations on various conditions which receive little attention or funding. They have added programs in an effort to better understand the needs of these patients. This is an effort to improve the process of approving treatments for under-recognized conditions, including paralytic conditions of the GI tract. G-PACT has been involved in some of these meetings in an effort to stress the importance of more meds for DTP.
In a teleconference last week with multiple organizations for a variety of conditions, the FDA stated that they are going to hold some regular meetings with about 20 organizations to determine how to best serve patient needs. This should enhance patient and FDA dialogue and hopefully lead to faster approval of medications for all kinds of conditions.
It has not been determined whether the FDA is going to focus on specific conditions such as gastroparesis, or on broader fields such as gastroenterology, neurology, etc. Regardless, this is an improvement in the FDA process and provides hope for those who have lingered for years while drugs have been denied."
"Linaclotide, produced by Ironwood Pharmaceuticals, is on the verge pf being approved for use in the US within the next few months. Although marketed for IBS with chronic constipation (IBS-C), it looks promising in the treatment of gastroparesis, chronic intestinal pseudo-obstruction, and colonic inertia as well. If you had success with Zelnorm in the past, this should be especially encouraging."
Edited May 25, 2012 at 12:56 pm